You are here: Industry Insights > CAR-T Therapy

News List

NHS England reaches deal with Gilead on CAR-T therapy Yescarta pharmaceutical-technology
October 09, 2018
National Health Service (NHS) England has reached an agreement with Gilead Sciences to provide the pharmaceutical company’s chimeric antigen receptor T-cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) for adults with large cell lymphoma.
Patient death following CAR-T therapy highlights serious manufacturing issues pharmaceutical-technology
October 08, 2018
It is reported that the accidental genetic engineering of a single leukemic cell during the early manufacturing of CAR-T therapy tisagenlecleucel for a phase I study caused the relapse and eventual death of one patient participating in the clinical trial.
Novartis collaborates with Cellular Biomedicine for CAR-T Therapy biospectrum
September 29, 2018
Novartis will be the exclusive holder of the marketing license.
NICE says no to Kymriah for adult lymphoma despite offer on price biopharmadive
September 20, 2018
Novartis slashed the U.K. list price for Kymriah by nearly a quarter compared to the U.S. for treating ALL patients under 25 whose disease was refractory, in relapse post-transplant or in second or later relapse.
Novartis' CAR-T Therapy Kymriah Receives EC Approval contractpharma
August 28, 2018
The European Commission (EC) has approved Novartis' Kymriah (tisagenlecleucel) for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory......
Novartis' Car-T Therapy Kymriah receives second FDA approval worldpharmanews
May 03, 2018
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication...
CAR-T therapy could be available to NHS patients this year pharmatimes
April 28, 2018
Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
Update on Priority Review by CDE: Acceptance of First CAR-T Therapy Clinical Application cccmhpie
February 02, 2018
On December 11, 2017, the first CAR-T project clinical application in China (CXSL1700201) filed by Nanjing Legend Biotechnology Co., Ltd. (hereinafter referred to as Nanjing Legend) was formally undertaken and accepted by the CDE
Is 2017 set to be the year we see a CAR-T therapy approved? Let’s find out from the leaders in the f fiercepharma
July 21, 2017
Using your body’s own cells, engineering them to target tumors and cure cancer sounds like something from a Sci-Fi movie but it’s not, it’s happening right now!
Juno ends development of CAR-T therapy JCAR015 following patient deaths firstwordpharma
March 03, 2017
Juno Therapeutics said that it will end development of the experimental CAR-T therapy JCAR015 in adults with relapsed or refractory acute lymphoblastic leukaemia (ALL) following safety issues observed in a mid-stage trial.

Previous page 1 2 3 Next page